For the past two weeks, global economic trends have been weighing on equities, with an Irish debt crisis, the possible raising of Chinese interest rates, and now a corruption scandal in India, markets have tried hard to keep their heads above water, but all to no avail. Most trading days have finished in the red as of late, helping to break already low levels of investor confidence. With international markets erupting with negative news and data, it can be easy to overlook events on the home front. Though earnings season for the third quarter of the year is over, there are still a few big name firms who have yet to report their most recent quarter's performance [see also Corruption Scandal Sinks India ETFs].
Today, before market open, medical technology manufacturer, Medtronic
Analysts predict the company to bring in an EPS of $0.81 with revenues nearing the $4 billion mark. The firm has hit their revenue predictions for the past year, but their EPS came up short last quarter, disappointing investors. However, the company remains an interesting play in the medical field for two reasons. First, Medtronic finds itself in a relatively inelastic line of business, as many people put their lives in the hands of the devices the company produces, and cannot get by without them. However, unlike many of the big pharma firms, Medtronic isn’t facing a patent cliff which threatens to destroy its profitability for years to come. Recent political events could also benefit the company, as a gridlocked central government will likely be unable to enact further health care legislation -- such as the controversial Affordable Care Act which was signed earlier this year -- which gives the company a potentially brighter future [see also MLP Exposure: ETF or ETN?].
With this earnings report set for today, the iShares Dow Jones U.S. Medical Devices Index Fund
[For more ETFs to watch make sure to sign up for our free ETF newsletter.]
More from ETFdb.com:
- PowerShares to Reshuffle ETF Indexes
- Smartphone ETF on the Horizon?
- This Week in ETFs: June 25th Edition
Disclosure: No positions at time of writing.
ETF Database is not an investment advisor, and any content published by ETF Database does not constitute individual investment advice. The opinions offered herein are not personalized recommendations to buy, sell or hold securities. From time to time, issuers of exchange-traded products mentioned herein may place paid advertisements with ETF Database. All content on ETF Database is produced independently of any advertising relationships. Read the full disclaimer here.
Covidien and Thermo Fisher Scientific are Motley Fool Inside Value picks. The Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.